No connection

Search Results

HAE vs UNH

HAE
Haemonetics Corporation
BULLISH
Price
$60.48
Market Cap
$2.81B
Sector
Healthcare
AI Confidence
82%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HAE
16.66
UNH
24.43
Forward P/E
HAE
11.43
UNH
16.08
P/B Ratio
HAE
3.11
UNH
3.11
P/S Ratio
HAE
2.13
UNH
0.66
EV/EBITDA
HAE
10.06
UNH
16.47

Profitability

Gross Margin
HAE
60.21%
UNH
18.53%
Operating Margin
HAE
21.01%
UNH
0.34%
Profit Margin
HAE
13.31%
UNH
2.69%
ROE
HAE
19.3%
UNH
12.54%
ROA
HAE
6.45%
UNH
3.9%

Growth

Revenue Growth
HAE
-2.7%
UNH
12.3%
Earnings Growth
HAE
28.4%
UNH
-99.9%

Financial Health

Debt/Equity
HAE
1.34
UNH
0.82
Current Ratio
HAE
1.75
UNH
0.79
Quick Ratio
HAE
1.04
UNH
0.7

Dividends

Dividend Yield
HAE
--
UNH
2.73%
Payout Ratio
HAE
0.0%
UNH
65.99%

AI Verdict

HAE BULLISH

HAE exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating a robust financial trajectory. While the stock is currently trading above its Graham Number ($39.87), it remains significantly undervalued relative to its growth-based intrinsic value ($107.08) and a PEG ratio of 0.92. Despite a bearish technical trend and slight revenue contraction (-2.70%), the company demonstrates exceptional operational efficiency with 28.4% earnings growth and a consistent track record of beating EPS estimates. The divergence between strong internal fundamentals and poor price performance suggests a value opportunity.

Strengths
Strong Piotroski F-Score (7/9) signaling high financial health
Attractive valuation with a PEG ratio of 0.92 and Forward P/E of 11.43
Exceptional earnings growth (28.4% YoY) and consistent EPS beats
Risks
Negative revenue growth (-2.70% YoY) indicating top-line stagnation
Bearish technical trend (0/100) suggesting lack of immediate market momentum
Moderate leverage with a Debt/Equity ratio of 1.34
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

HAE vs UNH: Head-to-Head Comparison

This page compares Haemonetics Corporation (HAE) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile